Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melissa G Lechner

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
JCI Insight|July 8, 2025
Polyfunctional T follicular helper cells drive checkpoint-inhibitor diabetes and are targeted by JAK inhibitor therapyNicole L Huang, Jessica G Ortega, Kyleigh Kimbrell, et al.
Science Translational Medicine|May 17, 2023
Clonally expanded, thyrotoxic effector CD8<sup>+</sup> T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditisMelissa G Lechner, Zikang Zhou, Aline T Hoang, et al.
Journal of the Endocrine Society|March 2, 2023
Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor-Induced HypophysitisZoe Quandt, Stephanie Kim, Javier Villanueva-Meyer, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 21, 2022
Pathogenic TNF-α drives peripheral nerve inflammation in an Aire-deficient model of autoimmunityYan Wang, Lily Guo, Xihui Yin, et al.
The Journal of Clinical Investigation|December 16, 2025
UTX coordinates TCF1 and STAT3 to control progenitor CD8+ T cell fate in autoimmune diabetesHo-Chung Chen, Madison F Bang, Hsing-Hui Wang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 7, 2022
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in OncologyJohn A Thompson, Bryan J Schneider, Julie Brahmer, et al.
Journal for Immunotherapy of Cancer|October 15, 2025
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitorsLing Zhu, Yee-Ming M Cheung, Cherie Chiang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 13, 2024
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024John A Thompson, Bryan J Schneider, Julie Brahmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2023
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) ConsortiumTalal El Zarif, Amin H Nassar, Elio Adib, et al.
Circulation. Heart Failure|October 30, 2019
Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical CenterLauren A Eberly, Aaron Richterman, Anne G Beckett, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
JCI Insight|July 8, 2025
Polyfunctional T follicular helper cells drive checkpoint-inhibitor diabetes and are targeted by JAK inhibitor therapyNicole L Huang, Jessica G Ortega, Kyleigh Kimbrell, et al.
Science Translational Medicine|May 17, 2023
Clonally expanded, thyrotoxic effector CD8<sup>+</sup> T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditisMelissa G Lechner, Zikang Zhou, Aline T Hoang, et al.
Journal of the Endocrine Society|March 2, 2023
Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor-Induced HypophysitisZoe Quandt, Stephanie Kim, Javier Villanueva-Meyer, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 21, 2022
Pathogenic TNF-α drives peripheral nerve inflammation in an Aire-deficient model of autoimmunityYan Wang, Lily Guo, Xihui Yin, et al.
The Journal of Clinical Investigation|December 16, 2025
UTX coordinates TCF1 and STAT3 to control progenitor CD8+ T cell fate in autoimmune diabetesHo-Chung Chen, Madison F Bang, Hsing-Hui Wang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 7, 2022
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in OncologyJohn A Thompson, Bryan J Schneider, Julie Brahmer, et al.
Journal for Immunotherapy of Cancer|October 15, 2025
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitorsLing Zhu, Yee-Ming M Cheung, Cherie Chiang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 13, 2024
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024John A Thompson, Bryan J Schneider, Julie Brahmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2023
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) ConsortiumTalal El Zarif, Amin H Nassar, Elio Adib, et al.
Circulation. Heart Failure|October 30, 2019
Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical CenterLauren A Eberly, Aaron Richterman, Anne G Beckett, et al.
Pageof 6